BioRestorative VP of R&D resigns claiming Good Reason; company disputes severance demand
BioRestorative Therapies, Inc.
Mr. Silva resigned as VP of R&D effective Sept 4, 2026, asserting 'Good Reason' under employment agreement due to alleged Change in Control from June 2026 board changes.
Silva demands ~$1.29M cash severance, equity award acceleration, and benefit continuation; company does not accept validity of agreement or his characterizations.
Board acknowledges resignation for records but reserves all rights; only accrued unpaid salary to be paid pending investigation.
Board investigating circumstances around Employment Agreement and agreements with former CEO and former CFO before any payments.
On September 4, 2026, BioRestorative Therapies, Inc. (the “ Company ”) received a notice of resignation from Mr. Silva from his employment with the Company, including as the Company’s Vice President of Research and Development, and from each other position (if any) he held as an officer of the Company, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Mr. Silva resigned as Vice President of Research and Development at BioRestorative Therapies, Inc..
Action
resigned
Role
Vice President of Research and Development
Exact text from the filing
On September 4, 2026, BioRestorative Therapies, Inc. (the “ Company ”) received a notice of resignation from Mr. Silva from his employment with the Company, including as the Company’s Vice President of Research and Development, and from each other position (if any) he held as an officer of the Company, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.